knowledge -WSS

knowledge

author：fashion 2025-10-01 15:40:21 - browse：86771

Illustration of a laptop on top of a TV with a hand sticking out, holding a newspaper. -- coverage from STAT — Adobe

WASHINGTON – If you live in this city, you’re probably awash in pharmacy benefit manager ads — whether you’re listening to an NPR podcast, reading the New York Times, streaming “Yellowstone,” or watching the U.S. Open Golf Championships. It doesn’t matter if it’s 5 a.m., primetime, or 11 p.m.; in between ads for dog joint supplements and the “Barbie” movie, you will inevitably learn about these middlemen of the prescription drug market.

Ads eviscerating and glorifying PBMs have been around for years. But they’ve intensified over the past three months as Congress scrutinizes PBMs’ role in shaping high drug prices. Over a half-dozen U.S. House and Senate Committees have started investigating PBMs, advancing bipartisan legislation to increase transparency in the industry; ban PBMs from charging more for a drug than what they pay (and pocketing the difference); and require them to pass all fees, rebates, and other payments they receive to insurers.

Lobbying groups have responded to this legislative push with dueling campaigns in the court of public opinion. On one side is the Pharmaceutical Care Management Association, the trade association representing PBMs, which argues that pharmaceutical companies are responsible for high drug prices. On the other side is the industry group PhRMA, which points the finger right back, saying that PBMs are really to blame. Both trade associations have launched ad campaigns worth millions of dollars, blanketing TV, radio, social media, print, and beyond.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： How to save PrEP access — and even expand it

hotspot

focus

WSS

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

Alabama IVF ruling threatens families facing fatal genetic disease

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Jerome Adams on the need for new antivirals for Covid

How one medical school became remarkably diverse

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

hotspot

knowledge

hotspot

Sports medicine is finally prioritizing gender equality

R1 RCM gets $5.8 billion buyout offer from private equity firm

Medicare details structure of new drug price negotiation program

Virginia high school admissions case could be legal follow

Hollywood unions extend contract negotiations for actors

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

Anesthesiologist group: stop taking Ozempic before surgery

6 phony surgeries that take placebo to the extreme

Walensky prepares to leave CDC — and Congress — behind

Alabama hospital puts IVF treatments on hold

entertainment

With competition flaring, obesity drug hits goal in liver disease study

State Dept. review finds Biden bears some blame for Afghanistan failures

Alabama IVF ruling threatens families facing fatal genetic disease

Trump demands the U.S. pay no more for drugs than other countries … again

New documents shed light on MD Anderson Cancer Institute feud

Why palliative psychiatry is worth discussing

hotspot

focus

focus

Wikipedia